)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Apimeds Pharmaceuticals
Apimeds Pharmaceuticals (APUS) investor relations material
Apimeds Pharmaceuticals has been acquired
Apimeds Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary4 May, 2026
Executive summary
Fiscal year 2025 marked a transformation with an IPO and the acquisition of MindWave Innovations, adding a digital asset segment to the biopharmaceutical business.
The company operates two segments: biopharmaceuticals (Apitox for knee osteoarthritis) and digital asset operations (MindWaveDAO, holding BTC, USDT, and NILA Tokens).
No revenue was generated from biopharmaceutical or digital asset operations in 2025; digital asset gains were recognized as other income.
Financial highlights
Net loss for 2025 was $6.0 million, up from $1.4 million in 2024, driven by increased R&D and G&A expenses.
Total operating expenses rose to $11.9 million in 2025 from $1.3 million in 2024.
Other income of $5.9 million in 2025 was primarily from digital asset gains post-MindWave acquisition.
Cash and equivalents at year-end 2025 were $1.6 million, with $8.0 million in restricted cash and $2.0 million in short-term investments.
Digital assets at fair value totaled $149.9 million as of December 31, 2025.
Outlook and guidance
The company expects continued operating losses as it advances Apitox clinical development and builds operational infrastructure.
Significant manufacturing costs for Apitox are anticipated in 2026.
Management plans to address liquidity needs through additional convertible note tranches, NILA Token sales, and potential equity or debt financing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Apimeds Pharmaceuticals
- IPO aims to fund late-stage trials for a novel bee venom therapy, but risks remain high.APUS
Registration Filing - IPO funds Phase III trials for novel OA/MS therapy; high risk, no revenue, major owner controls.APUSRegistration Filing
- IPO aims to fund late-stage trials for a novel bee venom therapy targeting OA and MS.APUSRegistration Filing
- IPO funds will advance Apitox clinical trials for OA and MS amid high risk and no revenue.APUSRegistration Filing
- IPO funds pivotal Apitox trials for OA/MS; no US revenue, high risk, major shareholder control.APUSRegistration Filing
- IPO targets $16.1M to fund Phase III OA trial for bee venom therapy; high risk, no revenue.APUSRegistration Filing
- IPO aims to fund U.S. trials for bee venom therapy; high risk, no revenue, majority control.APUSRegistration Filing
- IPO aims to fund late-stage trials for a novel bee venom therapy in OA and MS.APUSRegistration Filing
- Q3 2025 net loss rose to $1.78M as R&D and G&A costs surged post-IPO; cash runway extends 12 months.APUSQ3 2025
Apimeds Pharmaceuticals
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)